VectorY

VectorY B.V. was founded in August 2020 as a gene therapy company focused on the development of innovative therapies, such as vectorized antibodies for central nervous system and somatic diseases, with a particular emphasis on muscle-related conditions. The company owns research and development as well as manufacturing facilities, developing proprietary collaborative projects based on its novel AAV-based vectorized antibody and gene therapy platform. The candidate products are based on new vector technology, which will enable next-generation highly scalable manufacturing processes within VectorY's own manufacturing facilities. Our production capabilities will include a state-of-the-art multi-product GMP facility located in the Netherlands, capable of providing up to 2000L suspension AAV viral vector production for clinical and commercial supply.